加载中
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.
收盘时
US$11.61
−US$0.34 · -2.85%
盘后
US$11.61
US$0.00 · 0.00%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.
日内区间
当前US$11.61
52周区间
当前US$11.61
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
47
合理估值
情绪
55
多空交织
风险
59
风险偏高
动量
36
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.
日内区间
当前US$11.61
52周区间
当前US$11.61
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 2.44亿 USD | 355万 USD | 15.1万 USD | — | 2010万 USD |
| 销货成本 | 150.9万 USD | — | — | — | — |
| 毛利 | 2.43亿 USD | 355万 USD | 15.1万 USD | — | 2010万 USD |
| 研究与开发 | 1.3亿 USD | 1.74亿 USD | 1.35亿 USD | 8726.5万 USD | 5514.3万 USD |
| 销售、一般及管理费用 | 4684.9万 USD | 4075.4万 USD | 3483.4万 USD | 2752.5万 USD | 2133万 USD |
| 营业费用 | 1.72亿 USD | 2.14亿 USD | 1.7亿 USD | 1.15亿 USD | 7647.3万 USD |
| 利息收入 | — | — | — | 1000 USD | — |
| 利息支出 | — | — | — | 1000 USD | 4000 USD |
| 折旧和摊销 | 150.9万 USD | 122.9万 USD | 81.5万 USD | 67.4万 USD | 37.8万 USD |
| 营业利润 | 7062.3万 USD | −2.11亿 USD | −1.7亿 USD | −1.15亿 USD | −5637.3万 USD |
| 净利润 | 8701.4万 USD | −1.87亿 USD | −1.53亿 USD | −1.05亿 USD | −5874.4万 USD |
公司数据更新于 2026年10月13日。
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$20.33
上涨空间 75.11%价格历史记录不可用
最高：US$23.00平均的：US$20.33最低：US$18.00AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
